Rhinovirus vaccination: The case against

European Respiratory Journal

Volumn 37, Issue 1, 2011, Pages 5-7

  Papi, A ^a   Contoli, M ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CROSS REACTING ANTIBODY; GLUCOCORTICOID; INFLUENZA VACCINE; PROTEIN VP1; PROTEIN VP2; PROTEIN VP3; PROTEIN VP4; RHINOVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

EDITORIAL; GENETIC VARIABILITY; HUMAN RHINOVIRUS; IMMUNOGENICITY; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; RHINOVIRUS INFECTION; VACCINATION;

ANTIBODIES, VIRAL; HUMANS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; PEPTIDES; PICORNAVIRIDAE INFECTIONS; PROTEIN STRUCTURE, TERTIARY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHINOVIRUS; VACCINATION; VIRAL VACCINES; VIRUS DISEASES;

EID: 79251559076     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00145710     Document Type: Editorial

References (31)

1. Heikkinen T, Jarvinen A. The common cold. Lancet 2003; 361: 51-59.
2. Mallia P, Contoli M, Caramori G, et al. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Focus on virus induced exacerbations. Curr Pharm Des 2007; 13: 73-97.
3. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.
4. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114-1121. (Pubitemid 43726892)
5. Doull IJM, Lampe FC, Smith S, et al. Effect of inhaled corticosteroids on episodes of wheezing associated with viral infection in school age children: randomised double blind placebo controlled trial. BMJ 1997; 315: 858-862.
6. Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362: 1433-1438.
7. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-1373.
8. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339: b5106.
9. Ventre K, Randolph A. WITHDRAWN: Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2010; 5: CD000181.
10. Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70: 1079-1098.
11. Palmenberg AC, Spiro D, Kuzmickas R, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009; 324: 55-59.
12. Smith TJ. Antibody interactions with rhinovirus: lessons for mechanisms of neutralization and the role of immunity in viral evolution. Curr Top Microbiol Immunol 2001; 260: 1-28.
13. Fox JP. Is a rhinovirus vaccine possible? Am J Epidemiol 1976; 103: 345-354.
14. Message SD, Johnston SL. The immunology of virus infection in asthma. Eur Respir J 2001; 18: 1013-1025.
15. Message SD, Johnston SL. Host defense function of the airway epithelium in health and disease: clinical background. J Leukoc Biol 2004; 75: 5-17.
16. Perkins JC, Tucker DN, Knopf HL, et al. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Am J Epidemiol 1969; 90: 519-526.
17. Cooney MK, Wise JA, Kenny GE, et al. Broad antigenic relationships among rhinovirus serotypes revealed by cross-immunization of rabbits with different serotypes. J Immunol 1975; 114: 635-639.
18. Bardin PG, Fraenkel DJ, Sanderson G, et al. Amplified rhinovirus colds in atopic subjects. Clin Exp Allergy 1994; 24: 457-464.
19. Tyrrell DA. General virology and targets for therapy. In: Skoner DP., ed. Asthma and Respiratory Infections. New York, Marcel Dekker, Inc., 2001; pp. 209-220.
20. Rossmann MG, Arnold E, Erickson JW, et al. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985; 317: 145-153.
21. Palmenberg AC, Rathe JA, Liggett SB. Analysis of the complete genome sequences of human rhinovirus. J Allergy Clin Immunol 2010; 125: 1190-1199.
22. McCray J, Werner G. Different rhinovirus serotypes neutralized by antipeptide antibodies. Nature 1987; 329: 736-738.
23. Katpally U, Fu TM, Freed DC, et al. Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization. J Virol 2009; 83: 7040-7048.
24. Edlmayr J, Niespodziana K, Popow-Kraupp T, et al. Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J 2011; 37: 44-52.
25. Verdaguer N, Fita I, Reithmayer M, et al. X-ray structure of a minor group human rhinovirus bound to a fragment of its cellular receptor protein. Nat Struct Mol Biol 2004; 11: 429-434.
26. Colonno RJ, Callahan PL, Leippe DM, et al. Inhibition of rhinovirus attachment by neutralizing monoclonal antibodies and their Fab fragments. J Virol 1989; 63: 36-42.
27. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56: 839-847.
28. Register RB, Uncapher CR, Naylor AM, et al. Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding. J Virol 1991; 65: 6589-6596.
29. Staunton DE, Gaur A, Chan PY, et al. Internalization of a major group human rhinovirus does not require cytoplasmic or transmembrane domains of ICAM-1. J Immunol 1992; 148: 3271-3274.
30. Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med 2008; 14: 199-204.
31. Simmonds P, McIntyre CL, Savolainen-Kopra C, et al. Proposals for the classification of human rhinovirus species C into genotypically-assigned types. J Gen Virol 2010; 84: 10297-10310.